W. Ébert
Impact in
- Cancer Research top 5%
- Protease and Inhibitor Mechanisms
- Hematology top 5%
- Blood groups and transfusion
Papers in
- Oncology 33
- Peptidase Inhibition and Analysis 17
- Lung Cancer Research Studies 12
- Bone health and treatments 7
-
- Glycosylation and Glycoproteins Research 12
- Co-authors
- Eberhard Spieß (21 shared papers)D. Roelcke (12 shared papers)Bernd Werle (15 shared papers)H. Weicker (13 shared papers)T. Muley (7 shared papers)Hendrik Dienemann (5 shared papers)Thomas Muley (6 shared papers)Tamara T. Lah (9 shared papers)
In The Last Decade
W. Ébert
89 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 118
- Cancer Research 423
- Hematology 243
- Oncology 491
- Immunology and Allergy 77
- Physiology 228
Countries citing papers authored by W. Ébert
This map shows the geographic impact of W. Ébert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Ébert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Ébert more than expected).
Fields of papers citing papers by W. Ébert
This network shows the impact of papers produced by W. Ébert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Ébert. The network helps show where W. Ébert may publish in the future.
Co-authors
The 25 scholars most cited alongside W. Ébert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 164 | |
| 2 | CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. | 2004 | 67 |
| 3 | Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. | 2004 | 58 |
| 4 | 1972 | 57 | |
| 5 | 1994 | 54 | |
| 6 | Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. | 2005 | 53 |
| 7 | 1988 | 51 | |
| 8 | 1997 | 49 | |
| 9 | 2000 | 48 | |
| 10 | 1971 | 45 | |
| 11 | 2005 | 44 | |
| 12 | 1976 | 43 | |
| 13 | 1990 | 42 | |
| 14 | 1995 | 42 | |
| 15 | 1977 | 39 | |
| 16 | 2008 | 39 | |
| 17 | 2003 | 38 | |
| 18 | 1994 | 38 | |
| 19 | Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. | 2003 | 38 |
| 20 | 2006 | 38 |
About W. Ébert
W. Ébert is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Surgery, having authored 92 papers that have together received 1.8k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (20 papers), Peptidase Inhibition and Analysis (17 papers), Glycosylation and Glycoproteins Research (12 papers), Lung Cancer Research Studies (12 papers), Erythrocyte Function and Pathophysiology (8 papers), Neuroendocrine Tumor Research Advances (8 papers), Bone health and treatments (7 papers) and Blood groups and transfusion (6 papers). The work is most often cited by research in Cancer Research (423 citations), Hematology (243 citations), Oncology (491 citations), Immunology and Allergy (77 citations) and Physiology (228 citations). W. Ébert has collaborated with scholars based in Germany, Slovenia and Croatia. Frequent co-authors include Eberhard Spieß, D. Roelcke, Bernd Werle, H. Weicker, T. Muley, Hendrik Dienemann, Thomas Muley, Tamara T. Lah, Janko Kos and H. P. Geisen. Their work appears in journals such as Vox Sanguinis, Lung Cancer, Journal of Molecular Medicine, British Journal of Cancer and Clinical Chemistry and Laboratory Medicine (CCLM).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.